Myc Cancer Research Results

Myc, v-myc avian myelocytomatosis viral oncogene homolog: Click to Expand ⟱
Source: TCGA
Type:
Myc is a family of regulator genes and proteins that play a crucial role in cell cycle progression, apoptosis, and cellular transformation.
Myc is often found to be overexpressed or dysregulated in many types of tumors. This overexpression can lead to uncontrolled cell division and growth, contributing to the development and progression of cancer.
Myc is frequently overexpressed in various cancers, including hematological malignancies (like Burkitt lymphoma) and solid tumors (such as breast, lung, and colon cancers). This overexpression can result from genetic alterations, such as chromosomal translocations, amplifications, or mutations.

MYC is use as a clinical biomarker for risk biology-aggressiveness.
Scientific Papers found: Click to Expand⟱
4916- DSF,  Cu,    The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
- Review, Var, NA
TumCP↓, inhibits proliferation, migration, and invasion of malignant tumor cells.
TumCMig↓,
TumCI↓,
eff↑, divalent copper ions can enhance the antitumor effects of DSF
Imm↑, immunomodulatory properties of DSF
ROS↑, Elevated production of reactive oxygen species (ROS) and suppression of the ROS/NF-κB signaling pathway
NF-kB↓,
chemoP↑, DSF has been shown to effectively inhibit NF-κB pathway activity and augment the apoptotic impact of 5-fluorouracil (5-FU) on colorectal cancer cells when administered in conjunction with 5-FU
JNK↑, Activate the JNK signaling pathway
FOXO↑, In acute myeloid leukemia, DSF/Cu2+ enhances the expression of the oncogene FOXO and inhibits the expression of the oncogene MYC, inducing G0/G1 cell cycle arrest and tumor cell apoptosis
Myc↑,
TumCCA↑,
Apoptosis↑,
RadioS↑, DSF/Cu2+ enhances the efficacy of conventional chemotherapy and chemoradiation, while remaining cost-effective
PD-L1↑, DSF can upregulate PD-L1 expression by promoting DNMT1-mediated hypomethylation of IRF7
eff↑, DSF was found to markedly enhance the efficacy of anti-PD-1 antibody treatment
CSCs↓, Inhibition of cancer stem cells
Dose↝, DSF's oral dosage form is ineffective for cancer treatment due to its instability in the gastric environment and rapid degradation in the body
Half-Life↑, DSF encapsulated PEG-PLGA NPs have been shown to improve tumor site delivery and prolong systemic circulation half-life.


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   JNK↑, 1,   Myc↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   FOXO↑, 1,  

Migration ⓘ

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 1,   NF-kB↓, 1,   PD-L1↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 2,   Half-Life↑, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

Myc↑, 1,   PD-L1↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Myc, v-myc avian myelocytomatosis viral oncogene homolog
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:210  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page